1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Peripheral T-Cell Lymphomas (PTCL). This report provides information on the therapeutic development based on the Peripheral T-Cell Lymphomas (PTCL) dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Peripheral T-Cell Lymphomas (PTCL)
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Peripheral T-Cell Lymphomas (PTCL)-Pipeline Insights, 2014
Table of Contents
- Peripheral T-Cell Lymphomas (PTCL) Overview
- Peripheral T-Cell Lymphomas (PTCL) Pipeline Therapeutics
- Peripheral T-Cell Lymphomas (PTCL) Therapeutics under Development by Companies
- Peripheral T-Cell Lymphomas (PTCL) Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Peripheral T-Cell Lymphomas (PTCL) Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Peripheral T-Cell Lymphomas (PTCL) Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Peripheral T-Cell Lymphomas (PTCL) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products
- Peripheral T-Cell Lymphomas (PTCL) - Dormant Products
- Companies Involved in Therapeutics Development for Peripheral T-Cell Lymphomas (PTCL)
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Monotherapy Products
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Combination Products
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Route of Administration
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Route of Administration
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Molecule Type
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Molecule Type
- Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Discontinued Products
- Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Monotherapy Products
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Combination Products
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Route of Administration
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Route of Administration
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Molecule Type
- Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the US - Forecast

  • November 2016
    8 pages
  • Cancer  

  • United States  

View report >

Cancer Statistics in Russia

  • November 2016
    8 pages
  • Leukemia  

    Cancer  

    Radiography  

  • Russian Federat...  

View report >

Related Market Segments :

Lymphoma

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.